Jonathan C Fox
CIK 1655016 · See Remarks · last filed 2026-07-01
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Loading insider history…
Disclosed Exposure
$1.08M
Companies
3
Total Filings
40
Lifetime Open-Market Net
-$6.95M
Holdings By Company
Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| EWTX | Director | 24,833 | $43.52 | $1.08M | $300.4K | 13 | 2026-07-01 |
| Eidos Therapeutics, Inc. (EIDX) Delisted | See Remarks | 380,967 | — | — | -$7.28M | 24 | 2020-09-18 |
| MyoKardia, Inc. (MYOK) Delisted | Chief Medical Officer | 240,997 | — | — | $30.0K | 2 | 2016-05-06 |
Recent Filings · Page 3 of 4
40 filingsInsider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2020-04-27 | Eidos Therapeutics, Inc. (EIDX) Delisted | Sell (S) | −5,000 | -$250.0K | EDGAR |
| 2020-03-04 | Eidos Therapeutics, Inc. (EIDX) Delisted | Sell (S) | −10,000 | -$515.7K | EDGAR |
| 2020-02-19 | Eidos Therapeutics, Inc. (EIDX) Delisted | Mixed | −11,632 | -$540.0K | EDGAR |
| 2020-01-16 | Eidos Therapeutics, Inc. (EIDX) Delisted | Sell (S) | −10,000 | -$550.1K | EDGAR |
| 2020-01-09 | Eidos Therapeutics, Inc. (EIDX) Delisted | Gift (G) | −270 | $0 | EDGAR |
| 2019-12-05 | Eidos Therapeutics, Inc. (EIDX) Delisted | Mixed | −11,000 | -$589.0K | EDGAR |
| 2019-11-27 | Eidos Therapeutics, Inc. (EIDX) Delisted | Sell (S) | −10,000 | -$565.2K | EDGAR |
| 2019-11-22 | Eidos Therapeutics, Inc. (EIDX) Delisted | Sell (S) | −10,000 | -$551.1K | EDGAR |
| 2019-11-19 | Eidos Therapeutics, Inc. (EIDX) Delisted | Sell (S) | −15,000 | -$729.7K | EDGAR |
| 2019-10-16 | Eidos Therapeutics, Inc. (EIDX) Delisted | Sell (S) | −5,000 | -$180.8K | EDGAR |
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.